Impact News +++ Magnum Ice Cream Co serves up mixed first final results after demerger (Proactive Investors) +++ MAGNUM ICE CREAM Aktie -9,62%

INOVIO Aktie

>INOVIO Aktienkurs

1.33 EUR -2.2% (TradegateBSX)

Ask: 1.39 EUR / 2160 Stück

Bid: 1.33 EUR / 2270 Stück

Tagesumsatz: 148 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INOVIO Aktie über LYNX handeln

Intraday

1 Jahr

>INOVIO Performance

1 Woche: -3,5%

1 Monat: -0,7%

3 Monate: -19,0%

6 Monate: +10,6%

1 Jahr: -25,3%

laufendes Jahr: -8,1%

>INOVIO Aktie

Name:

INOVIO PHARMACEUTICAL INC

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45773H4092 / A400EJ

Symbol/ Ticker:

GBM (Frankfurt) / INO (NASDAQ)

Kürzel:

FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO

Index:

Webseite:

https://inovio.com/

Profil:

Inovio Pharmaceuticals, Inc. is a biotechnology co..
>Volltext..

Marktkapitalisierung:

97.57 Mio. EUR

Unternehmenswert:

62.78 Mio. EUR

Umsatz:

0.15 Mio. EUR

EBITDA:

-72.86 Mio. EUR

Nettogewinn:

-90.84 Mio. EUR

Gewinn je Aktie:

-2.17 EUR

Schulden:

8.42 Mio. EUR

Liquide Mittel:

30.73 Mio. EUR

Operativer Cashflow:

-74.73 Mio. EUR

Bargeldquote:

0.73

Umsatzwachstum:

-14.95%

Gewinnwachstum:

9.14%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INOVIO

Letzte Datenerhebung:

12.02.26

>INOVIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 68.7 Mio. St.

Frei handelbar: 99.58%

Leerverk. Aktien: 18.12%

Rückkaufquote: -47.52%

Mitarbeiter: 134

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 334.35%

Bewertung:

KGV: -

KGV lG: -

KUV: 466.98

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -1551.12%

Gewinnmarge: -59281.69%

Operative Marge: -49202.88%

Managementeffizenz:

Gesamtkaprendite: -122.52%

Eigenkaprendite: -328.45%

>INOVIO Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Impfstoffentwicklung/ Impfstoffhersteller, Onkologie/ Krebs- Behandlung

>INOVIO Chart & Kurs - NASDAQ

>INOVIO News

11.02.26 - 15:24	INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to......

11.02.26 - 02:39	IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc. (PR Newswire)
	SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a......

11.02.26 - 00:06	INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025. A class action lawsuit has......

15.01.26 - 16:06	CORRECTIONINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO (PR Newswire)
	NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

02.01.26 - 15:12	Looking Into Inovio Pharmaceuticals Inc′s Recent Short Interest (Benzinga)
	read more...

29.12.25 - 16:45	Inovio drops as respiratory papillomatosis asset denied accelerated review (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.12.25 - 16:36	Inovio-Aktie bricht ein: FDA hegt Zweifel an beschleunigtem Zulassungsverfahren (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.12.25 - 14:09	FDA Accepts for Review INOVIO′s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) (PR Newswire)
	PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and......

19.12.25 - 22:12	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
	PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an......

18.11.25 - 14:09	INOVIO to Participate in December Investor Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate......

14.11.25 - 19:45	Inovio (INO) Upgraded to Buy: Here′s Why (Zacks)
	Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

11.11.25 - 15:06	INOVIO-Aktie gibt nach: Kapitalerhöhung über 25 Mio. Dollar mit Abschlag platziert (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 14:48	INOVIO announces pricing of $25M public offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 14:42	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the......

11.11.25 - 07:39	Inovio Pharmaceuticals drops 6%, proposes equity offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 01:33	Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 00:12	INOVIO Announces Proposed Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced......

10.11.25 - 23:36	Inovio: Innovationsfokus trotz Nettoverlust im dritten Quartal 2025 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 23:33	Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms \| DelveInsight (PR Newswire)
	The oropharyngeal cancer market is anticipated to grow during the forecast period (2025–2034), driven by the launch of emerging therapies such as PDS Biotechnology's Versamune HPV, Inovio Pharmaceuticals and MedImmune's INO-3112/MEDI0457, Cue Biopharma's CUE-101, BioNTech's BNT113, and......

10.11.25 - 22:12	Inovio Pharmaceuticals GAAP EPS of -$0.87 misses by $0.45 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mag alles Leid und Schatten sein - doch diese süße Sonnenstunde nicht, und nicht der Duft vom roten Klee, und nicht das tiefe, zarte Wohlgefühl in meiner Seele. - Hermann Hesse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram